Laboratory Studies Confirm the Effectiveness of BETADINE® Gargle and Mouthwash Against COVID-19 Virus
30.6.2020 17:57:00 EEST | Business Wire | Press release
Laboratory testing completed at the Tropical Infectious Diseases Research and Education Center (TIDREC) at the University of Malaya, Malaysia, has confirmed the effectiveness of BETADINE® Gargle and Mouthwash against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease. BETADINE® is manufactured and distributed in Malaysia by Mundipharma.
BETADINE® Gargle and Mouthwash was tested for virucidal activity in two concentrations, undiluted (PVP-I 1% w/v) and at a 1:2 dilution (PVP-I 0.5% w/v) under established European (EN14476) methodology and standards. The testing demonstrated strong in-vitro virucidal activity, with the tested products killing 99.99% of the SARS-CoV-2 virus in just 15 seconds.
The TIDREC research has been accepted by the British Dental Journal (BDJ) and was published as a Letter on 26 June 2020. The journal is published by Springer Nature on behalf of the British Dental Association.
“Laboratory testing has shown that BETADINE® Gargle and Mouthwash is effective against COVID-19 and could contribute to our ongoing efforts to keep people and communities safe,” said Dr Pouya Hassandarvish, the Lead Investigator of the Study and the postdoctoral fellow researcher at TIDREC, University of Malaya.
“These results confirm our view that BETADINE® Gargle and Mouthwash, used appropriately and in conjunction with other preventative treatment options including PPE, could play a role in limiting the spread of infections, including COVID-19,” said Raman Singh, Mundipharma CEO.
“It also provides the medical and dental community with a science-based assurance that they are using a product that is specifically studied against COVID-19,” he added.
Previously, BETADINE® antiseptic products containing Povidone-iodine (PVP-I) have been proven effective against a wide range of viruses, including coronaviruses that have caused major outbreaks such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The BETADINE® antiseptic range contains Povidone-iodine (PVP-I), which is effective against a wide range of microorganisms, including bacteria, viruses and fungi and is typically used in hospitals and homes.
About TIDREC
TIDREC serves as a focal point for national and international collaborative research for academic institutions and research industries in Malaysia. TIDREC also emphasizes on education and development of human skills. By advocating safe laboratory science, TIDREC aspires to be an internationally recognized centre of excellence in tropical infectious diseases research and education that serves the health needs of global communities.
TIDREC was the first research centre in the country to install fully certified modular biosafety level 2 & 3 laboratories for research involving highly virulent pathogens. TIDREC is also the only centre currently operating a mock biosafety level 3 training facility. The centre also houses the WHO Collaborating Centre for Arbovirus Reference & Research. The centre offer services such as drug screening, validation test for diagnostic kits and research collaboration on vector-borne diseases.
TIDREC mission is to advance knowledge by focusing on research in neglected tropical infectious diseases that have a potential impact on the global community.
About Mundipharma
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high-quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
About BETADINE®
The BETADINE® range of products have been trusted by hospitals and consumers around the world for over 60 years to prevent and treat infections. Over the last few years, Mundipharma has expanded the BETADINE® range of products to include Povidone-iodine and non-povidone iodine ranges for the prevention, treatment and maintenance of a range of conditions from upper respiratory tract infections, wound infections, feminine hygiene and infections and outbreaks to personal and hand hygiene. In-vitro and clinical studies have demonstrated that BETADINE® Povidone-iodine kills a broad range of bacteria, viruses and fungi including antibiotic-resistant strains.
®: BETADINE is a registered trademark of Mundipharma
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005731/en/
Contact information
For further information please contact:
Alice George
Principal Consultant
AG Global Communications
A-13-4, Tiara Faber
456, Jalan Desa Utama
Taman Desa
58100 Kuala Lumpur
Malaysia
Email: alice.agcomm@gmail.com
Mobile: +60196008157
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting26.3.2026 22:30:00 EET | Press release
Spring is in full swing at the “World’s Most Famous Building.” The Empire State Building (ESB) today announced a vibrant lineup of spring events in NYC, which include special experiences, treat pop-ups, and an iconic tower lighting that captures the joy and color of the beautiful season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326216271/en/ Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting “The Empire State Building Observation Deck has transformed into a celebration of the season and one of the best things to do in NYC this spring,” said Dan Rogoski, observatory general manager. “Whether it’s views beside our butterfly installation, sweet pop-ups, or a chance to spot the Easter Bunny, there is something special for every visitor.” Flutter of Color: The Empire State Building installed a brand-new photo opportunity on the 86th Floor Observati
Venture Global and Edison Announce Calcasieu Pass Arbitration Settlement26.3.2026 22:15:00 EET | Press release
Today, Venture Global and Edison jointly announced the signature of a commercial agreement for the settlement of the pending arbitration between the two companies concerning the Calcasieu Pass project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326559130/en/ Completion of the settlement is expected by the end of Q2 2026, at which point the arbitration will be terminated. The agreement fully resolves the arbitration in its entirety. As part of the settlement, Edison and Venture Global have also agreed to the delivery to Europe of additional cargoes beyond those envisaged under the long-term contract, to support gas supplies primarily to the Italian market. The first delivery is scheduled for May 2026, in Italy, at the Adriatic LNG Terminal. The agreement represents a significant step in strengthening commercial cooperation between the parties and it establishes a foundation for further future deliveries in the context
Reply Recognized as a Microsoft Frontier Partner for Enterprise AI Delivery26.3.2026 20:06:00 EET | Press release
Reply [EXM, STAR: REY] announces it has been recognized as a Microsoft Frontier Partner within the Microsoft AI Cloud Partner Program, earning the Frontier Partner Badge for demonstrating advanced capabilities in delivering AI-first solutions across Cloud & AI Platforms, AI Business Solutions, and Security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326965586/en/ The recognition reflects Reply’s capabilities across the Microsoft ecosystem, built through the work of its specialized companies – including Aim Reply, Business Elements Reply, Cluster Reply, Root16 Reply, Solidsoft Reply, Valorem Reply, WM Reply and Zest Reply – supporting enterprise organizations in designing, implementing, and operating AI solutions on Microsoft platforms across real-world business scenarios. The Frontier Partner badge recognizes partners that demonstrate advanced AI driven capabilities and meet rigorous badge requirements at the time of
InterSystems nimittänyt terveydenhuoltotoiminnan johtajaksi tohtori Tim Ferrisin, entisen NHS- ja Mass General ‑johtajan26.3.2026 20:00:00 EET | Tiedote
InterSystems on luovien datateknologiaratkaisujen tarjoaja, jonka ratkaisuihin on tallennettu yli miljardi terveystietotietuetta maailmanlaajuisesti. Yritys ilmoitti tänään nimittäneensä terveydenhuoltotoiminnan johtajaksi lääketieteen tohtori Tim Ferrisin. Nimityksestä ilmoitettiin samaan aikaan, kun terveydenhuoltoalan johtajat kokoontuvat vuoden 2026 HIMSS Global Health Conference & Exhibition ‑tapahtumaan. Roolissaan Ferris pääsee soveltamaan kattavaa toimialakokemustaan, kun hän ohjaa yrityksen terveydenhuoltoratkaisujen kliinistä ja strategista suuntaa maailmanlaajuisesti. Laajan kokemuksensa turvin hän toimii maailmanlaajuisten terveydenhuoltojärjestelmien ja hallitusten strategisena neuvonantajana ja suunnittelee räätälöityjä teknologiaratkaisuja, jotka perustuvat todellisiin johtotason tarpeisiin. Samalla hän edistää akateemista tutkimustaan terveysdata-arkkitehtuurista sekä johtaa julkista keskustelua tekoälyn ja hoidon tarjoamisen yhdistämisestä. Ferris tuo InterSystemsiin a
SLB Announces Dates for First-Quarter 2026 Results Conference Call26.3.2026 19:00:00 EET | Press release
SLB (NYSE:SLB) will hold a conference call on April 24, 2026, to discuss the results for the first quarter ending March 31, 2026. The conference call is scheduled to begin at 11:00 a.m. US Eastern time and a press release regarding the results will be issued at 7:00 a.m. US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (833) 470-1428 within North America or +1 (404) 975-4839 outside of North America approximately 10 minutes prior to the start of the call and the access code is 742955. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/972985185 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until May 1, 2026, and can be accessed by dialing +1 (866) 813-9403 within North America or +1 (929)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
